Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial
Acta Ophthalmologica · 2025
DOI: 10.1111/aos.17429 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Emmanuel Kobia-Acquah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Atropine, Choroid, Myopia, Refraction, Ocular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
To investigate 2‐year changes in macular choroidal thickness (ChT) in children receiving 0.01% atropine eyedrops and its relationship with spherical equivalent refraction (SER) progression and axial length (AL) elongation.
Methods
A total of 250 myopic children aged 6–16 years (167%–0.01% atropine, 83‐placebo) were enrolled in the MOSAIC ( ISRCTN36732601 ) clinical trial. Participants with complete 2‐year ChT (Topcon Triton Swept‐Source OCT), SER, and AL data were included in this study. Changes in macular ChT at 2 years and associations with changes in SER and AL elongation were analysed using linear mixed models.
Results
A total of 187 children (126%–0.01% atropine, 61‐placebo) were included in the analysis. Choroidal thickness over 2 years was stable in the 0.01% atropine compared with placebo group, which exhibited consistent thinning in subfoveal (mean ± SE: 0.49 ± 2.22 μm vs. −9.46 ± 2.69 μm; p = 0.034), parafoveal (1.40 ± 1.73 μm vs. −8.11 ± 2.08 μm; p = 0.002), and perifoveal (0.80 ± 1.25 vs. −6.17 ± 1.69; p = 0.002) macular subfields. Choroidal thickening was observed in participants with slower axial eye growth and myopia progression, regardless of their treatment group. Mediation analysis indicated that atropine 0.01% had a significant effect on ChT, with 68.3% of the effect being direct and 31.7% mediated through axial length changes. For SER, the direct effect on ChT was 80%, with the remaining 20% mediated by SER changes.
Conclusions
Myopic participants treated with 0.01% atropine exhibited stable ChT over 2 years, whereas the placebo group showed consistent thinning. The effect of atropine 0.01% on ChT was only partially explained by axial length and SER changes, indicating a direct effect of atropine treatment on the choroid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.
- Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Australia.
- Department of Ophthalmology, Children's Health Ireland at Temple Street Hospital, Dublin, Ireland.
ORCID-Profile: Emmanuel Kobia-Acquah, Gareth Lingham, James Loughman
Zitieren
APA
Kobia-Acquah, E., Lingham, G., Flitcroft, D. I., & Loughman, J. (2025). Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial. Acta Ophthalmologica. https://doi.org/10.1111/aos.17429
Vancouver
Kobia-Acquah E, Lingham G, Flitcroft DI, Loughman J. Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial. Acta Ophthalmologica. 2025. doi:10.1111/aos.17429
BibTeX
@article{KobiaAcquah2025,
author = {Kobia-Acquah, Emmanuel and Lingham, Gareth and Flitcroft, Daniel Ian and Loughman, James},
title = {Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial},
journal = {Acta Ophthalmologica},
year = {2025},
doi = {10.1111/aos.17429}
}
EUVIMED